Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.40 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.39 |
| ▸ | ADK | P55263 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12920212 | 1.00 | ADORA3 (0.45) | ADORA3ADORA2AADORA1P2RY12SLC29A1 | |
| SCHEMBL19840345 | 0.95 | ADORA3 (0.47) | ADORA3ADORA2AADORA1P2RY12ADK | |
| SCHEMBL16244658 | 0.88 | SLC29A1 (0.52) | ADORA3ADORA2AADORA1SLC29A1ADK | |
| SCHEMBL12920253 | 0.88 | SLC29A1 (0.46) | ADORA3ADORA2AADORA1SLC29A1ADK | |
| SCHEMBL412698 | 0.84 | ADORA3 (0.36) | ADORA3ADORA2AADORA1P2RY12 | |
| SCHEMBL12920215 | 0.84 | ADORA3 (0.36) | ADORA3ADORA2AADORA1P2RY12 | |
| SCHEMBL12920214 | 0.84 | TAS1R3 (0.45) | — | |
| SCHEMBL412282 | 0.84 | TAS1R3 (0.45) | — | |
| SCHEMBL19840344 | 0.81 | ADORA3 (0.37) | ADORA3ADORA2AADORA1P2RY12 | |
| SCHEMBL3189329 | 0.80 | TYMP (0.52) | ADORA2AP2RY12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065386-A1 | SYNTHESIS OF LABILE BASE PROTECTED - MODIFIED DEOXY & MODIFIED RIBO NUCLEOSIDES, CORRESPONDING PHOSPHORAMIDITES AND SUPPORTS AND THEIR USE IN HIGH PURITY OLIGONUCLEOTIDE SYNTHESIS | CHEMGENES CORPORATION | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065386-A1 | SYNTHESIS OF LABILE BASE PROTECTED - MODIFIED DEOXY & MODIFIED RIBO NUCLEOSIDES, CORRESPONDING PHOSPHORAMIDITES AND SUPPORTS AND THEIR USE IN HIGH PURITY OLIGONUCLEOTIDE SYNTHESIS | RNMT, POLRMT, RNGTT | ADORA3 451/4885ADORA2A 153/4885ADORA1 807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.